Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating on Tocagen with a $28 price target after the company announced that the Phase 3 trial of Toca 511 and Toca FC in recurrent high-grade glioma will continue without modification. The analyst had always assumed that the most likely scenario would be that the trial would continue until the final interim analysis in Q4 or 2019. Any dismissive views on Tocagen present a "strong opportunity" ahead of the year-end catalyst, Piros tells investors in a research note. He continues to believe that positive survival data will favor Toca 511 and Toca FC versus chemotherapy.